2019/01/15

Shinozaki T, Mansournia MA. Hazard ratio estimators after terminating observation within matched pairs in sibling and propensity score matched designs. Int J Biostat. 2019, online.

2019/01/08

Yamaguchi K, Kamatari Y, Ono F, Shibata H, Fuse T, Elhelaly A, Fukuoka M, Kimura T, Hosokawa-Muto J, Ishikawa T, Tobiume M, Takeuchi Y, Matsuyama Y, Ishibashi D, Nishida N, Kuwata K. A designer molecular chaperone against transmissible spongiform encephalopathy slows down the progression of the disease in mice and macaques. Nature Biomed Eng. 2019; In press.

2018/12/28

Shitara K, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. Ann Oncol. 2018. doi: 10.1093/annonc/mdy526. [Epub ahead of print]